VEGFA and renal cell carcinoma: On the other hand, for tyrosine kinase inhibitors (TKIs) targeting the VEGF pathway, such as cabozantinib and sunitinib, studies have addressed the caution that their concurrent treatment with anticoagulant agents, including DOACs, in renal cell carcinoma harbored a greater risk of bleeding than did anti‐VEGF TKIs alone.19, 20